Hologic (NASDAQ:HOLX)‘s stock had its “hold” rating restated by research analysts at Royal Bank of Canada in a research report issued on Friday. They presently have a $44.00 price objective on the medical equipment provider’s stock. Royal Bank of Canada’s price target indicates a potential upside of 16.56% from the company’s previous close.

Other equities research analysts have also recently issued research reports about the company. BidaskClub cut Hologic from a “hold” rating to a “sell” rating in a report on Saturday, January 13th. Evercore ISI assumed coverage on Hologic in a report on Wednesday, January 3rd. They set an “outperform” rating and a $50.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $50.00 price target on shares of Hologic in a report on Thursday, February 1st. Stifel Nicolaus lowered shares of Hologic from a “buy” rating to a “hold” rating and lowered their price objective for the company from $45.00 to $42.00 in a research note on Friday. Finally, Cowen upgraded shares of Hologic from a “market perform” rating to an “outperform” rating and set a $51.00 price objective on the stock in a research note on Monday, December 11th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Hologic has an average rating of “Buy” and an average price target of $48.36.

Shares of Hologic (HOLX) opened at $37.75 on Friday. The firm has a market capitalization of $10,438.97, a P/E ratio of 18.41, a PEG ratio of 1.76 and a beta of 0.77. The company has a current ratio of 0.79, a quick ratio of 0.61 and a debt-to-equity ratio of 0.79. Hologic has a twelve month low of $35.33 and a twelve month high of $46.80.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.50 by $0.05. The company had revenue of $791.10 million for the quarter, compared to analysts’ expectations of $785.80 million. Hologic had a return on equity of 20.75% and a net margin of 34.53%. The business’s revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 earnings per share. sell-side analysts forecast that Hologic will post 2.25 EPS for the current year.

In related news, VP Karleen Marie Oberton sold 1,023 shares of the firm’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $39.84, for a total transaction of $40,756.32. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Elaine Ullian sold 9,282 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $40.50, for a total transaction of $375,921.00. The disclosure for this sale can be found here. 0.79% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Hall Laurie J Trustee grew its position in Hologic by 10.2% in the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after buying an additional 225 shares during the last quarter. Sentry Investment Management LLC grew its position in Hologic by 1.9% in the second quarter. Sentry Investment Management LLC now owns 18,491 shares of the medical equipment provider’s stock worth $839,000 after buying an additional 353 shares during the last quarter. Creative Planning grew its position in Hologic by 8.2% in the fourth quarter. Creative Planning now owns 15,396 shares of the medical equipment provider’s stock worth $658,000 after buying an additional 1,161 shares during the last quarter. AT Bancorp grew its position in Hologic by 2.2% in the fourth quarter. AT Bancorp now owns 62,329 shares of the medical equipment provider’s stock worth $2,664,000 after buying an additional 1,323 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System grew its position in Hologic by 0.3% in the third quarter. State Board of Administration of Florida Retirement System now owns 406,630 shares of the medical equipment provider’s stock worth $14,919,000 after buying an additional 1,351 shares during the last quarter. Hedge funds and other institutional investors own 92.77% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Hologic (HOLX) Rating Reiterated by Royal Bank of Canada” was reported by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The original version of this article can be accessed at https://www.dailypolitical.com/2018/02/11/hologic-holx-rating-reiterated-by-royal-bank-of-canada.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.